It looks like you're using an Ad Blocker.
Please white-list or disable AboveTopSecret.com in your ad-blocking tool.
Thank you.
Some features of ATS will be disabled while you continue to use an ad-blocker.
originally posted by: Kurokage
a reply to: iwanttobelieve70
Well at least someone is willing to post something and not just bullcrap about shills and the like. Thank you...
That is American for you, were you allow congressional lobbying and unlimited political campaign contributions. I'm British and we don't really have as much of that kind of sponsership on TV here.
The Youtube video doesn't tell how many years that those clips were collected over, if it's 6 months or 6 years? I would be interested to know.
The rise in spending by the pharmaceutical industry on advertising on TV in the United States didn't appear to drastically change but the Statista website limted my view with wanting me to sign up.
From what I could see, it's been a steady rise from 2016 till 2020 but no numbers for a real comparision.
That also doesn't get away from the fact that the website linked in the OP is lying about the deaths of the people shown.
originally posted by: Kurokage
a reply to: iwanttobelieve70
Can you Experimental Gene Therapy damage deniers do something to make your case besides whining off-topic and dissing and trashing the OP? It’s tiresome.
——————————————————————————————————-
Well at least someone is willing to post something and not just bullcrap about shills and the like. Thank you...
That is American for you, were you allow congressional lobbying and unlimited political campaign contributions. I'm British and we don't really have as much of that kind of sponsership on TV here.
The Youtube video doesn't tell how many years that those clips were collected over, if it's 6 months or 6 years? I would be interested to know.
The rise in spending by the pharmaceutical industry on advertising on TV in the United States didn't appear to drastically change but the Statista website limted my view with wanting me to sign up.
From what I could see, it's been a steady rise from 2016 till 2020 but no numbers for a real comparision.
That also doesn't get away from the fact that the website linked in the OP is lying about the deaths of the people shown.
originally posted by: carewemust
RED ALERT 9.20.2022
For those (like me) who have never seen the actual evidence, take a look at what Embalmers/Morticians are removing from the arteries and veins of people who were Covid-19 vaccinated before they died.
Very Sad, but a Must Watch: www.bitchute.com...
No wonder the White House and U.S. Congress exempted themselves from being injected with these hideous Covid-19 vaccines!
Baloney. There are lots of great threads here with solid sources that aren’t random bitchute videos. I guess my question is, why waste so much time here if that’s what you think? 🤔 I mean you being right up there above the rest of us with all the important people that you know in high places and all?
originally posted by: Kurokage
a reply to: iwanttobelieve70
I don't trust MSM, but I don't trust the even worse bitchute opinion piece videos with no data at all, which is what's mostly posted in these types of threads on ATS.
Most have no data what so ever to back up the claims made, and the nonsence comments of "you won't find any 'cause they're covering it up".
Like I've posted in other threads, I know people who've work mid to high level management in the NHS and thought of a giant cover up is laughable.
Several mRNA vaccines are used on the population in the U.S. I started predicting the dangers of mRNA vaccines before March 2021 and update my findings periodically. My prior model study enabled me to identify many flaws in clinical trials, side-effect evaluation methods and mechanism studies, and I also considered consistent failure in predicting drug side effects in the past and systematic failure of FDA in keeping out dangerous drugs from market. I found that the risks of vaccination cannot be determined by experiments alone and must be determined by using a combination of methods. By studying mRNA expression dynamics and kinetics, I predict that vaccination with mRNA vaccines may increase cancer risks, multiple organ failure risks, earlier death risks, genome alteration speeds by one or more mechanisms, alter the normal selection process for viral evolution resulting in more virulent viruses, and aggravate chronic diseases or cause healed diseases to relapse. Two root problems are practical inability to control expression sites and severe adverse reactions from repeated vaccination. Based on mRNA bio-distribution, the mRNA mainly strikes the liver and other vital organs, and poses grave dangers to persons whose vascular functional reserves are relatively small, or whose vascular systems are temporarily burdened by other causes such as viral infections or life activities. If an mRNA vaccine is administered on a pregnant woman by second or booster shots, spike protein synthesis in fetus brain disrupts the highly regulated protein synthesis processes, resulting in potential brain damages. In less than a year, most of my early predicted damages are being materialized or are on the track to hit the population. In this update, I present a benefits-and-risks map to show how the number of deaths caused by mRNA vaccines is grossly underestimated and why claimed benefits like 95% effectiveness rate and 90% death rate reduction are meaningless and misleading.
Therapeutic Ab drugs targeting SARS-CoV-2 S-protein have shown high preventive efficacy against disease development1,2,3. In addition, current SARS-CoV-2 mRNA vaccines for humans also target the S-protein on viruses as a critical antigen4. These mRNA vaccines generate robust neutralizing Abs5,6,7, but for both Ab drugs and vaccines targeting the S-protein, the possible induction of Ab-dependent enhancement (ADE) of infection is a concern8,9,10,11. Recent reports have demonstrated that neutralizing mAbs against S-protein can exhibit ADE activity in a limited window of Ab concentrations12,13,14. An important issue requiring reconsideration is that the cells used to evaluate ADE potential are different in each report. In many cases, Fc-receptor (FcR)-positive and angiotensin-converting enzyme 2 (ACE2, the major receptor for SARS-CoV-215,16,17)-negative cells lines (Raji, THP-1, and K562) are used as host cells for infection of SARS-CoV-2 pseudo-viruses expressing S-protein or authentic SARS-CoV-212,13,14,18,19. These reports have demonstrated that some anti-S protein mAbs have the potential to induce ADE of infection. The observed ADE can be blocked in the presence of FcR-blocker, demonstrating FcR dependence. Likewise, the Ab drugs casirivimab and imdevimab1,20,21, which target the SARS-CoV-2 S-protein, have also been evaluated by using FcR-positive and ACE2-negative cell lines (U937, THP-1, IM9, K562, and Raji)22. In this case, the report concluded that these mAbs have no ADE activity. In contrast, recent reports have demonstrated that some plasma samples from COVID-19 patients can enhance SARS-CoV-2 infection only in cells expressing both FcR and ACE223,24. We also recently reported that ADE observed with sera from COVID-19 convalescents is FcR- and ACE2-dependent25. Therefore, current experimental conditions for evaluating ADE in vitro are inconsistent.
We have reported that human iPS cell-derived, immortalized, and ACE2- and TMPRSS2-expressing myeloid cell lines (Mylc cell lines) are highly susceptible to SARS-CoV-2 infection25. The infection of SARS-CoV-2 in Mylc cell lines was FcR- and ACE2-dependent. In the present study, we reevaluated whether the approved therapeutic Ab drugs (casirivimab, imdevimab, and sotrovimab26,27) have any potential to cause ADE even in FcR- and ACE2-positive cells. In addition, we investigated sera from mRNA (Moderna)-vaccinated individuals in terms of ADE-causing potential by using the same double-positive cells. Here, we show that the casirivimab and imdevimab mAbs have the ability to induce ADE, but sotrovimab does not. Furthermore, some sera from individuals vaccinated with the mRNA vaccine targeting the S-protein also exhibited ADE potential against infection with the original strain. All sera examined, including sera showing neutralizing activity against the original Wuhan strain of SARS-CoV-2, exhibited no neutralizing activity against Omicron. Rather, some ADE activity was observed in some sera.
e have shown that anti-SARS-CoV-2 S-protein neutralizing mAbs as whole molecules (human IgG1) can function as ADE-causing Ab (Fig. 1). These results raise the possibility that SARS-CoV-2 mRNA vaccines targeting the S-protein also induce ADE-causing Abs as well as neutralizing Abs. Next, we examined whether sera from mRNA (Moderna)-vaccinated volunteers have neutralizing or ADE activities, how long these activities last, and how they change in a time-dependent manner. Clone 35 cells were cultured with authentic SARS-CoV-2 virus (original strain) along with or without titrated sera from the same volunteer (HC2, Fig. 3A). Neutralizing activity was not detected in serum collected on day 27 after the first vaccination, but was detected at the highest concentration (1/100 dilution) of serum collected on days 20 and 52 after the second vaccination (Fig. 3A and Supplemental Fig. 6A). Simultaneously, obvious ADE activity was also detected at a diluted concentration (1/10,000 dilution) of serum. Importantly, serum collected on day 98 after the second vaccination exhibited no neutralizing activity at all under the serum dilutions examined, but maintained clear ADE activity (Fig. 3A). Sera from six individuals (including the same individual, HC2, shown in Fig. 3A) on day 98 after the second vaccination exhibited either neutralizing activity (HC3 and 5, Fig. 3B and Supplemental Fig. 6B) or no neutralizing activity (HC1, 2, 4, and 6, Fig. 3B and Supplemental Fig. 6B). However, in all these sera examined, ADE activity was detected to a greater or lesser degree
Sera collected on day 133 (Fig. 3C) after the second vaccination maintained almost the same pattern with the results on day 98 (Fig. 3B). On day 175 (Fig. 3D), ADE activity was observed only at the highest concentration in some sera, but with a relatively low magnitude. Some sera still maintained neutralizing activity at the highest concentration of serum (1/100 dilution, Supplemental Fig. 6D). Taken together, these results demonstrate that after vaccinations, neutralizing Abs are induced and persist for a long time in some individuals, but ADE-causing Abs also exist from the early stage and persist for a longer period than do neutralizing Abs in some individuals (HC2 and HC4 in Fig. 3B–D). It is noteworthy that ADE observed at a higher concentration of serum, that is at low dilution (1/100), might mean a more vulnerable stage in terms of susceptibility to infection, because no neutralizing activity was detected.
Finally, we examined the effect of sera after vaccination against infection with the SARS-CoV-2 Omicron strain. Clone 35 cells were cultured in the presence of sera collected before vaccination (Supplemental Fig. 7A) or on day 175 after the second vaccination (Supplemental Fig. 7B) along with authentic SARS-CoV-2 Omicron virus. Although some sera maintained neutralizing activity against the original strain (Supplemental Fig. 6D) even on day 175 after the second vaccination, none of these sera had neutralizing activity against Omicron (Supplemental Fig. 7B). Rather, one serum (HC6) exhibited some ADE activity
It has also been reported that neutralizing Abs induced after mRNA vaccinations decrease in a time-dependent manner31. Accordingly, we observed diminishing neutralizing activity in some vaccinated individuals in a time-dependent manner (Fig. 3A and Supplemental Fig. 6A). Simultaneously, the dominant ADE activity was observed at high concentrations of serum.
The Omicron strain has been found to have many mutations in the S-protein33,34. These mutations result in reduced or zero effectiveness of Cas and Imd mAbs against the Omicron strain29,35. We also confirmed this in our experimental setting (Fig. 2). In addition to changes in the reactivity of mAbs to Omicron, we observed different behavior of Omicron in the ADE assay compared with the SARS-CoV-2 original strain (Supplemental Figs. 6D and 7B). Some sera from mRNA-vaccinated volunteers (collected on day 175 after the second vaccination) maintained neutralizing activity against the SARS-CoV-2 original strain (Supplemental Fig. 6D). In contrast, none of these sera exhibited neutralization, and some of them caused enhancement of infection with Omicron
SCIENCEEEEEE
These results demonstrate that Abs raised by double vaccination (at least on day 175 after the second vaccination, Supplemental Fig. 7B) are less effective against Omicron as reported36, and suggest that the Omicron strain has acquired the ability to escape attack by pre-existing anti-SARS-CoV-2 Abs and in part can utilize infection-enhancing mechanisms, possibly including ADE, as a means of survival.
originally posted by: Oldcarpy2
a reply to: Kurokage
Do some folk distrust the MSM so much that they get their weather forecast and traffic news from Bitchute?
Hundreds of millions of SARS-CoV-2 mRNA-LNP vaccine doses have already been administered to humans. However, we lack a comprehensive understanding of the immune effects of this platform. The mRNA-LNP-based SARS-CoV-2 vaccine is highly inflammatory, and its synthetic ionizable lipid component responsible for the induction of inflammation has a long in vivo half-life. Since chronic inflammation can lead to immune exhaustion and non-responsiveness, we sought to determine the effects of pre-exposure to the mRNA-LNP on adaptive immune responses and innate immune fitness. We found that pre-exposure to mRNA-LNPs or LNP alone led to long-term inhibition of the adaptive immune response, which could be overcome using standard adjuvants. On the other hand, we report that after pre-exposure to mRNA-LNPs, the resistance of mice to heterologous infections with influenza virus increased while resistance to Candida albicans decreased. The diminished resistance to Candida albicans correlated with a general decrease in blood neutrophil percentages. Interestingly, mice pre-exposed to the mRNA-LNP platform can pass down the acquired immune traits to their offspring, providing better protection against influenza. In summary, the mRNA-LNP vaccine platform induces long-term unexpected immunological changes affecting both adaptive immune responses and heterologous protection against infections. Thus, our studies highlight the need for more research to determine this platform’s true impact on human health.
We bring experimental evidence that pre-exposure to mRNA-LNPs or its LNP component affects innate and adaptive immune responses. Pre-exposure to mRNA-LNPs led to long-term inhibition of the adaptive immune responses, which the use of adjuvants could overcome. On the other hand, we report that after pre-exposure to mRNA-LNPs, the resistance of mice to heterologous infections with influenza virus increased, while resistance to Candida albicans decreased. We also detected a general neutropenia in the mRNA-LNP exposed mice. Interestingly, mice pre-exposed to mRNA-LNPs can pass down the acquired immune traits to their offspring. In summary, the mRNA-LNP vaccine platform induces long-term immunological changes that can affect both adaptive immune responses and heterologous protection against infections, some of which can be inherited by the offspring. More studies are needed to understand the mechanisms responsible for these effects and determine this platform’s impact on human health.
The mRNA-LNP vaccine platform gained much attention with the ongoing SARS-CoV-2 pandemic. Initially, this vaccine platform was thought to be non-inflammatory since the mRNA has been modified and purified to limit innate immune activation [1–3]. At the same time, the lipid nanoparticle (LNP) component was considered an inert carrier and protector of the mRNA. However, it has recently been shown that the synthetic ionizable lipid component of the LNPs is highly inflammatory [4], and that this inflammation is critical to support the induction of adaptive immune responses. These LNPs mixed with proteins induce comparable responses to mRNA-LNPs [5]. The platform can support the induction of adaptive immune responses in the absence of a variety of different inflammatory cytokines, -pathways, and innate immune cells
The acute side effects reported with the mRNA-LNP vaccine platform are diverse and likely associated with its highly inflammatory nature and partially mediated by innate immune responses [4,8]. In addition to the induction of specific T- and B-cell activation, certain vaccines or infections can affect long-term innate immune responses by either increasing or decreasing the activation of innate immune cells [9]. Furthermore, the innate immune reprogramming induced by certain vaccines can interfere with immune responses induced by other vaccines [9]. The possible short and long-term immunological changes mediated by the mRNA-LNP vaccine outside the induction of antigen-specific anti-SARS-CoV-2 responses are unknown. A recent human study awaiting peer-review reported innate and adaptive immune reprogramming with this platform [10], while single-cell RNA-seq studies on human white blood cells derived from vaccinated people also revealed significant changes in innate immune cells [11]. Whether the reported changes are long-lasting and can influence immune fitness or interfere with the responses induced by other vaccines remains to be determined.
Baloney. There are lots of great threads here with solid sources that aren’t random bitchute videos. I guess my question is, why waste so much time here if that’s what you think? 🤔 I mean you being right up there above the rest of us with all the important people that you know in high places and all?
While tolerance to COVID-19 vaccination is considered satisfactory, a phenomenon of myocarditis, although rare, is becoming a safety concern in mRNA COVID-19 vaccination. The presence of low residual levels of double-strand RNA (dsRNA) has been reported in mRNA COVID-19 vaccine preparations. dsRNA is a known inducer of immune-inflammatory reactions. dsRNA present in vaccine nanoparticles may be suspected to be at the origin of the still unexplained cases of myocarditis.
Myocarditis is an inflammatory phenomenon of the heart muscle; it is associated with pericarditis, an inflammation more specifically related to the pericardium, which is designed as myopericarditis. In the following text, the term myocarditis will be used to design myocarditis, pericarditis or myopericarditis. The highest rates of myocarditis were initially reported in young male adults [9]. In the reported cases, COVID-19 infection was ruled out and none of the patients had clinical signs or laboratory findings compatible with an autoimmune disease.
Some investigators consider that host inflammatory cell responses are at the origin of these cases of myocarditis. Clearly, inflammation of the myocardium involving macrophage and dendritic cells plays a key role in triggering myocarditis in general
Double-strand RNA as an impurity in mRNA vaccines
Before approving drugs and health products, health authorities deliver key authorizations usually based on publicly available reports. This was the case recently with the EMA regarding COVID-19 mRNA vaccines [13,14]. The EMA reported the presence in the Comirnaty and Moderna vaccine preparations of low residual levels of double-strand RNA (dsRNA) [13,14], which is one of the main impurities produced during mRNA vaccine preparation [15]. One of the characteristics of mRNA liposomal forms of vaccines is to be entirely produced in vitro. Thus, mRNA vaccines avoid the risks associated with other vaccine platforms, including live viruses, viral vectors, inactivated viruses and subunit protein vaccines. While the simplicity of the approach of synthesizing in vitro-transcribed (IVT) mRNA is appealing, technical difficulties remain, including impurities and particularly the generation of dsRNA contaminants [16] as indicated above. The current methods used to purify IVT mRNA vaccine preparations vary in terms of technical performance and, at best, allow the removal of 90% of dsRNA when using HPLC, as reported by the developers of mRNA vaccines [17]. According to reports and vaccine developers, the presence of short segments of dsRNA at low level along with purified mRNA cannot be totally ruled out [17].
Notably, dsRNA is known to be a strong exogenous inducer of immune-inflammatory reactions involving well-identified intracellular signaling cascades and mediators (Figure 1). dsRNA is detected by antigen-presenting cells, endothelial cells and the airway epithelium [18], and gives rise to dose-related innate immune activation [17]. Mechanistically, dsRNA is a toll-like receptor 3 (TLR3) agonist, a strong inducer of humoral- and cell-mediated immunity that is mainly generated through inflammatory cytokines [19]. dsRNA leads to cellular release of TNF-α and, as reported recently, of TNF-α and IFN-γ, the main drivers of the cytokine storm and cell death occurring in severe forms of COVID-19 [20]. Moreover, a dsRNA-activated protein kinase (PKR) has been found to play a key role in inflammatory signaling [21] including TNF-α secretion. Of particular interest in the context of the COVID-19, a recent report describes that the interferon-induced, dsRNA-actived antiviral enzyme OAS1 significantly contributes to the antiviral response against SARS-CoV-2 [22]. OAS1 recognizes short structures of SARS-CoV-2 RNAs [22]. Importantly, a genetic polymorphisms in OAS1 introduces a variable sensing of dsRNA and influences COVID-19 severity
This leads to the next unavoidable question: can the presence of dsRNA in mRNA vaccines, even at low concentration, explain some of the undesired effects? In the case of myocarditis, it should be noted that when packaged in lipid nanoparticles, dsRNA is preferentially transferred to phagocytic monocytic-derived cells, such as macrophages and dendritic cells, which are key actors in immunity [24]. Recent studies indicate that precursors of dendritic cells patrol the blood and communicate with immature dendritic cells residing in peripheral tissues such as the kidneys, skin and myocardium. Dendritic cells trigger immune responses in lymphoid tissues upon early sensing of infectious pathogens. Globally, dendritic cells form a sentinel network that modulates immune responses with the distinct ability to produce protective immunity or tolerance to self. Dendritic cells also play a major role in the pathophysiology of inflammatory diseases. As a result, the uptake of dsRNA by dendritic cells is suspected of triggering immune reactivity and inflammatory reactions.
While tolerance to COVID-19 vaccination is considered satisfactory, a phenomenon of myocarditis, although rare.....
Two large European epidemiological studies have estimated the excess risk of myocarditis following vaccination with COVID-19 Vaccine Pfizer/BioNTech and COVID-19 Vaccine Moderna. One study showed that in a period of 7 days after the second dose of COVID-19 Vaccine Pfizer/BioNTech there were about 27 (95% CI 26 - 28) extra cases of myocarditis in 12-29 year old males per million compared to unvaccinated individuals, and for COVID-19 Vaccine Moderna there were about 132 (95% CI 130 – 133) extra cases of myocarditis in 12-29 year old males per million. In another study, in a period of 28 days after the second dose of the COVID-19 Vaccine Pfizer/BioNTech there were 57 [95% CI 39 – 75] extra cases of myocarditis in 16-24 year old males per million compared to unvaccinated persons, and for COVID-19 Vaccine Moderna. there were 188 (95% CI 96 – 280) extra cases of myocarditis in 16-24 year old males per million individuals compared to unvaccinated individuals. These studies have shown that these events are very rare post vaccination with the mRNA vaccines, and that these events are more frequent in younger males. The findings of these studies are consistent with the trends seen in the Yellow Card data.
International data has shown that these suspected events have been observed to occur most frequently approximately 3 days after the first vaccine and 2 days after the second vaccine, and both UK and international data have identified that the large majority of suspected events occur within 7 days of vaccination. In the UK the body of evidence shows that there is similar frequency of reporting after the first and second dose.
Longer term follow-up in both the UK and US to at least 90 days following identification of cases of suspected myocarditis after COVID-19 Vaccine Pfizer/BioNTech and COVID-19 Vaccine Moderna found that the majority of individuals were fully recovered and back to normal activities.
Myocarditis and pericarditis happen very rarely in the general population, and it is estimated that in the UK there are about 60 new cases of myocarditis diagnosed per million patients per year and about 100 new cases of pericarditis diagnosed per million patients per year. Myocarditis is also known to be associated with COVID-19 infection, with an estimated 1,500 cases of myocarditis per million patients with COVID-19.
The MHRA will continue to closely monitor reports of suspected myocarditis and pericarditis with all currently authorised COVID-19 vaccines.
Pharmacokinetic studies have not been conducted with COVID-19 mRNA Vaccine BNT162b2 and are generally not considered necessary to support the development and licensure of vaccine products for infectious diseases (WHO, 2005; WHO, 2014).
No absorption studies were conducted for COVID-19 mRNA Vaccine BNT162b2 since the route of administration is intramuscular (IM).
Study R-20-0072 evaluated the in vivo potential biodistribution of COVID-19 mRNA Vaccine BNT162b2 in mice using luciferase expression as a surrogate reporter. Protein expression was demonstrated at the site of injection and to a lesser extent, and more transiently, in the liver after mice received an IM injection of RNA encoding luciferase in an LNP formulation like BNT162b2.
Luciferase expression was identified at the injection site at 6 hours after injection and diminished to near baseline levels by day 9
No excretion studies have been conducted with COVID-19 mRNA Vaccine BNT162b2.
No PK drug interaction studies have been conducted with COVID-19 mRNA Vaccine BNT162b2. This is acceptable and in line with relevant guidelines (WHO 2005; WHO 2014).
Single dose toxicity No single dose toxicity studies have been performed. This is acceptable and in line with relevant guidelines (WHO 2005; WHO 2014).
Toxicokinetics No toxicokinetic studies have been performed with the vaccine. This is consistent with WHO guidelines on the nonclinical evaluation of vaccines (WHO 2005).
Genotoxicity No genotoxicity studies are planned for BNT162b2, as the components of all vaccine constructs are lipids and RNA that are not expected to have genotoxic potential (WHO, 2005).
Carcinogenicity Carcinogenicity studies with BNT162b2 have not been conducted as the components of all vaccine constructs are lipids and RNA that are not expected to have carcinogenic or tumorigenic potential. Carcinogenicity testing is generally not considered necessary to support the development and licensure of vaccine products for infectious diseases (WHO, 2005).
Reproductive and developmental toxicity Fertility and early embryonic development and embryofoetal development In the general toxicity studies, macroscopic and microscopic evaluation of male and female reproductive tissues showed no evidence of toxicity.
A combined fertility and developmental study (including teratogenicity and postnatal investigations) in rats is ongoing.
Prenatal and postnatal development, including maternal function No such studies have been done.
Studies in which the offspring (juvenile animals) are dosed and/or further evaluated No such studies have been done.
Local tolerance No such studies have been done. The assessments made as part of the general toxicity study should suffice and a separate study is not needed.
originally posted by: carewemust
RED ALERT 9.20.2022
For those (like me) who have never seen the actual evidence, take a look at what Embalmers/Morticians are removing from the arteries and veins of people who were Covid-19 vaccinated before they died.
Very Sad, but a Must Watch: www.bitchute.com...
No wonder the White House and U.S. Congress exempted themselves from being injected with these hideous Covid-19 vaccines!